| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥7.4B | ¥6.8B | +9.1% |
| Operating Income | ¥2.2B | ¥1.2B | +79.1% |
| Ordinary Income | ¥2.4B | ¥1.3B | +82.7% |
| Net Income | ¥2.5B | ¥1.3B | +86.1% |
| ROE | 14.1% | 8.8% | - |
FY2026 Q3 cumulative results: Revenue 7.42 billion yen (YoY +9.1%), Operating Income 2.23 billion yen (YoY +79.1%), Ordinary Income 2.36 billion yen (YoY +82.7%), Net Income 2.48 billion yen (YoY +86.1%). The company demonstrated strong profit growth significantly outpacing revenue expansion. Gross profit margin reached 71.7% with SG&A expenses controlled at 41.6% of revenue, resulting in an operating margin of 30.1%. The Antibody-related segment remained the core business with diagnostic reagent services as the primary revenue driver, while the Cosmetics segment recorded an operating loss of 463 million yen. ROE improved to 14.1% driven by net profit margin expansion to 33.4%, though asset turnover remained moderate at 0.356x. Cash and deposits stood at 8.93 billion yen against short-term debt of 142 million yen, providing substantial liquidity coverage. However, working capital efficiency deteriorated with DSO extending to 109 days and inventory days reaching 99 days, resulting in a cash conversion cycle of 752 days.
Revenue increased 9.1% YoY to 7.42 billion yen, primarily driven by growth in the Antibody-related segment. Diagnostic reagent services expanded 14.9% to 644 million yen, representing the largest revenue contributor. TG Silkworm services grew 12.3% to 76 million yen, while laboratory testing services contracted 57.7% to 20 million yen, indicating a significant structural shift in service mix. The Cosmetics segment revenue declined 50.0% to 2.2 million yen, reflecting ongoing challenges in this non-core business area. Gross profit margin of 71.7% remained exceptionally high, indicating strong pricing power and favorable product mix in high-value-added diagnostic and biotechnology services.
Operating income surged 79.1% to 2.23 billion yen, substantially outpacing revenue growth due to effective SG&A expense management. SG&A expenses totaled 3.08 billion yen, representing 41.6% of revenue, demonstrating operational leverage as revenue scaled. The operating margin expanded significantly to 30.1% from 17.6% in the prior year period. Non-operating income contributed approximately 130 million yen net, comprising interest income, foreign exchange gains, and equity method investment gains, pushing ordinary income to 2.36 billion yen (up 82.7%). The gap between ordinary and net income was minimal, with net income reaching 2.48 billion yen (up 86.1%), indicating no material extraordinary items or tax anomalies. This represents a revenue up, profit up pattern with profit growth significantly exceeding revenue growth, driven by margin expansion and cost control rather than top-line acceleration.
The Antibody-related segment generated revenue of 7.40 billion yen with operating income of 2.24 billion yen, representing an operating margin of 30.2%. This segment constitutes the core business with 97.1% of total revenue. Within this segment, diagnostic reagent services contributed 643.7 million yen (86.8% of segment revenue), TG Silkworm services 76.0 million yen (10.2%), and laboratory testing services 20.3 million yen (2.7%). The segment demonstrated strong profitability with operating income growing substantially from 123.6 million yen in the prior year period. The Cosmetics segment recorded revenue of 2.2 million yen with an operating loss of 463 thousand yen, compared to a profit of 1.1 million yen in the prior year. This segment represents 0.3% of total revenue and continues to operate at a loss, indicating potential strategic review requirements. The margin differential between segments is substantial, with the Antibody-related segment achieving 30.2% operating margin while the Cosmetics segment posted negative margins at approximately -21.4%, highlighting the concentration of profitability in the biotechnology-focused core business.
[Profitability] ROE of 14.1% reflects strong shareholder returns driven primarily by net profit margin of 33.4%, substantially above typical levels for the biotechnology services sector. Operating margin of 30.1% expanded 12.5 percentage points from 17.6% YoY, demonstrating significant operating leverage. Gross profit margin of 71.7% indicates high-value service offerings with strong pricing power. [Cash Quality] Cash and deposits of 8.93 billion yen provide coverage of 6.29 times short-term debt of 142 million yen, ensuring robust liquidity. However, working capital management shows deterioration with receivables collection period extending to 109 days and inventory turnover slowing to 99 days. Work-in-process inventory represents 46.1% of total inventory, indicating extended production cycles. [Investment Efficiency] Total asset turnover of 0.356x remains modest, though consistent with research-intensive business models requiring substantial long-term asset investments. Investment securities increased 78.9% to 1.70 billion yen, representing strategic portfolio expansion. [Financial Health] Equity ratio of 84.5% reflects conservative capital structure with minimal leverage. Current ratio of 529.7% and quick ratio of 509.7% indicate exceptional short-term solvency. Total debt of 162 million yen (comprising 142 million yen short-term and 20 million yen long-term) results in debt-to-equity ratio of 0.092, confirming low financial risk profile. Long-term debt decreased 43.1% YoY to 20 million yen.
Cash and deposits increased 2.18 billion yen YoY to 8.93 billion yen, reflecting strong profit accumulation with net income of 2.48 billion yen representing the primary driver of cash generation. Total assets expanded 2.49 billion yen to 20.87 billion yen, with investment securities increasing 753 million yen to 1.70 billion yen, indicating strategic investment activity. Working capital dynamics show mixed signals as accounts payable increased 40 million yen (149.5% growth) suggesting enhanced supplier credit utilization, while inventory expanded 144 million yen (33.5%) with particular concentration in work-in-process materials. The inventory build, combined with extended receivables collection period of 109 days, implies operating cash flow conversion may lag reported earnings. Retained earnings grew 2.48 billion yen (58.3%) to 6.74 billion yen, demonstrating capital accumulation through profit retention. Long-term borrowings declined 152 million yen (43.1%) indicating debt reduction activity. The cash position provides coverage of 6.29 times short-term liabilities, confirming adequate liquidity buffers. However, the extended cash conversion cycle of 752 days indicates significant capital tied up in working capital, potentially constraining effective cash generation despite strong profitability metrics.
Ordinary income of 2.36 billion yen versus operating income of 2.23 billion yen reflects non-operating net contribution of approximately 130 million yen, comprising primarily interest income, dividend income, and foreign exchange gains. Non-operating income represents 1.8% of revenue, a modest proportion indicating core business operations drive the majority of profitability. The differential between ordinary and net income is minimal, with net income of 2.48 billion yen slightly exceeding ordinary income, suggesting no material extraordinary items or unusual tax effects impacted reported earnings. The consistency between operating performance and bottom-line results indicates sustainable earnings quality from a P&L perspective. However, working capital metrics raise concerns regarding cash realization of reported profits. Receivables collection period of 109 days and inventory turnover of 99 days, particularly with work-in-process representing 46.1% of total inventory, suggest extended conversion cycles. The cash conversion cycle of 752 days substantially exceeds industry norms, indicating that reported earnings may not fully translate to operating cash flow in the near term. While profitability metrics are strong, the absence of disclosed operating cash flow data and the deteriorating working capital efficiency metrics warrant careful monitoring of actual cash generation relative to accrual-based earnings.
Full-year guidance projects revenue of 10.25 billion yen (YoY +5.7%), operating income of 2.40 billion yen (YoY +14.6%), and ordinary income of 2.40 billion yen (YoY +14.4%). Q3 cumulative progress rates stand at 72.4% for revenue, 93.0% for operating income, and 98.3% for ordinary income. Operating income progress significantly exceeds the standard 75% benchmark for Q3, suggesting strong first nine-month performance with potential for guidance upward revision or conservative initial forecasts. The company is tracking ahead of plan on profitability metrics while revenue pacing is slightly below the 75% benchmark, indicating margin expansion is driving results. The projected full-year operating margin of 23.4% (240M/1,025M) would represent improvement from the prior year's 21.0%, though below the Q3 cumulative achieved margin of 30.1%, suggesting anticipated margin normalization or investment spending in Q4. EPS forecast of 28.45 yen implies full-year net income of approximately 2.65 billion yen based on 9.31 million outstanding shares, representing an 86.3% YoY increase. The Q3 cumulative net income of 2.48 billion yen represents 93.6% progress against this implied full-year target, indicating strong likelihood of meeting or exceeding earnings guidance.
Annual dividend forecast is 6.00 yen per share for the full fiscal year. Based on the forecasted net income of approximately 2.65 billion yen and 9.31 million shares outstanding, total projected dividends of approximately 55.9 million yen would represent a payout ratio of approximately 21.1%, a sustainable level given the strong cash position and profitability. No interim dividend was paid in Q2, and no year-end dividend is explicitly mentioned in the current period, suggesting the 6.00 yen forecast may represent a year-end payment concentration. The moderate payout ratio provides substantial retained earnings for reinvestment while initiating shareholder returns. With cash reserves of 8.93 billion yen and minimal debt obligations, dividend payment capacity is secure from a balance sheet perspective. However, the working capital efficiency concerns and extended cash conversion cycle of 752 days warrant monitoring to ensure operating cash flow adequately supports dividend payments alongside business investment needs. No share buyback activities are disclosed in the current reporting period.
Working capital deterioration represents the primary operational risk, with cash conversion cycle extending to 752 days driven by receivables collection period of 109 days and inventory days of 99 days. Work-in-process inventory comprising 46.1% of total inventory indicates extended production and realization cycles, creating risk of obsolescence or valuation adjustments if products fail to achieve commercialization. This efficiency deterioration could constrain cash generation despite strong reported profitability, potentially impacting dividend sustainability or growth investment capacity. Quantitatively, the CCC extension implies approximately 2.0 billion yen of capital tied up in working capital that could otherwise be deployed for shareholder returns or strategic initiatives.
Revenue concentration in the Antibody-related segment at 97.1% of total revenue, with diagnostic reagent services representing 86.8% of core segment revenue, creates dependency risk on a narrow customer base and product portfolio. The sharp 57.7% decline in laboratory testing services from 47.9 million yen to 20.3 million yen YoY demonstrates vulnerability to demand shifts in specific service lines. The Cosmetics segment posted operating losses of 463 thousand yen versus prior year profit of 1.1 million yen, indicating diversification efforts have not succeeded. This concentration limits revenue resilience if core diagnostic markets face regulatory changes, competitive pressures, or technological disruption.
Financial structure risk emerges from short-term debt representing 87.7% of total interest-bearing debt. While absolute debt levels are low at 162 million yen against cash of 8.93 billion yen, the maturity concentration creates refinancing considerations. Additionally, investment securities increased 78.9% to 1.70 billion yen, introducing mark-to-market valuation risk that could impact equity values and comprehensive income. The securities represent 8.1% of total assets, creating moderate exposure to financial market volatility.
[Industry Position] (Reference - Proprietary Analysis)
The company demonstrates exceptional profitability metrics relative to pharmaceutical industry peers. Operating margin of 30.1% substantially exceeds the industry median of negative 218.2% (IQR: -628.8% to -14.9%), positioning the company in the top tier of operational efficiency. This disparity reflects the company's focus on high-margin diagnostic services and biotechnology platforms rather than capital-intensive drug development typical of the broader pharmaceutical sector. Net profit margin of 33.4% similarly outperforms the industry median of negative 216.8% (IQR: -725.8% to -24.6%), indicating sustainable business model economics.
ROE of 14.1% significantly exceeds the industry median of negative 35.8% (IQR: -91.4% to -6.1%), reflecting superior capital efficiency. The equity ratio of 84.5% compares favorably to the industry median of 67.8% (IQR: 62.1% to 79.1%), positioning the company in the upper quartile for financial stability. Current ratio of 529.7% far exceeds the industry median of 6.62x (IQR: 4.66x to 9.18x), though this extraordinarily high level may indicate excess liquidity that could be more productively deployed.
Revenue growth of 9.1% YoY contrasts with the industry median decline of 12.5% (IQR: -22.1% to -2.5%), demonstrating resilient demand for the company's services while many pharmaceutical peers face top-line pressures. Asset turnover of 0.356x exceeds the industry median of 0.17 (IQR: 0.05 to 0.24), indicating more efficient asset utilization despite the research-intensive business model.
Working capital metrics present relative concerns. Receivables turnover of 109 days compares to industry median of 151.6 days (IQR: 86.8 to 300.8), suggesting moderately better collection efficiency, though the absolute level remains elevated. Inventory turnover of 99 days appears favorable against the industry median of 281.6 days (IQR: 145.9 to 302.0), though the high work-in-process concentration warrants specific attention not captured in aggregate industry comparisons.
(Industry: Pharmaceuticals, n=13 companies, Comparison: 2025-Q3, Source: Proprietary Analysis)
The earnings analysis reveals a company achieving exceptional profitability metrics with operating margin of 30.1% and net profit margin of 33.4%, substantially exceeding pharmaceutical industry benchmarks and demonstrating the value proposition of specialized diagnostic and biotechnology services. The 79.1% operating income growth significantly outpacing 9.1% revenue growth indicates successful margin expansion through operational leverage, with SG&A expense control enabling profit flow-through. ROE of 14.1% reflects strong shareholder returns supported by high profit margins, though constrained by moderate asset turnover characteristic of research-intensive business models. The company has achieved 93.0% of full-year operating income guidance through Q3, suggesting high probability of meeting or exceeding targets with potential for upward revision given the conservative revenue pacing at 72.4% of target.
Working capital management represents the most significant operational concern requiring monitoring, with cash conversion cycle extending to 752 days reflecting receivables collection period of 109 days and inventory days of 99 days. The work-in-process concentration at 46.1% of total inventory indicates extended production cycles inherent in biotechnology manufacturing, creating timing delays between production expenditures and revenue realization. This working capital deterioration suggests reported earnings may not fully convert to operating cash flow in near-term periods, though the substantial cash position of 8.93 billion yen provides buffer capacity. The absence of disclosed operating cash flow data limits ability to assess cash earnings quality comprehensively, making this a priority disclosure item for future periods.
The dividend forecast of 6.00 yen per share representing approximately 21% payout ratio appears sustainable given strong profitability and substantial cash reserves, though working capital efficiency improvements would enhance confidence in long-term distribution capacity. Revenue concentration in the Antibody-related segment at 97.1% of total revenue creates dependency on diagnostic reagent and TG Silkworm service demand, with the sharp contraction in laboratory testing services and continued Cosmetics segment losses highlighting execution risks in diversification efforts. The investment securities increase of 78.9% to 1.70 billion yen introduces portfolio allocation considerations regarding optimal capital deployment between organic growth, financial investments, and shareholder returns.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.